Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
November 8, 2022 4:01 PM ESTUDENYCA® net sales of $45.4 million in the third quarter 2022 CIMERLI launched in the United States on October 3rd Planning underway for 2023 commercial launches of toripalimab, YUSIMRY and UDENYCA® OBI Conference call today at 5 p.m. ET
REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights:
RECENT BUSINESS HIGHLIGHTS
CIMERLI (ranibizumab-eqrn), was approved in August 2022 by... More